搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3(CDKN2A) ELISA kit

Human Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3(CDKN2A) ELISA kit

  • 中文名稱：
    人細(xì)胞周期蛋白依賴性激酶抑制劑2A，亞型1/2/3(CDKN2A)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-EL005089HU
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人細(xì)胞周期蛋白依賴性激酶抑制劑2A，亞型1/2/3(CDKN2A)酶聯(lián)免疫試劑盒（CSB-EL005089HU）為雙抗夾心法ELISA試劑盒，定量檢測(cè)血清、血漿、組織勻漿、細(xì)胞裂解物樣本中的CDKN2A含量。CDKN2A 是重要的腫瘤抑制基因，在細(xì)胞周期調(diào)控中發(fā)揮關(guān)鍵作用。其編碼的 p16 蛋白可抑制 CDK4/6 激酶活性，阻滯細(xì)胞從 G1 期進(jìn)入 S 期。研究發(fā)現(xiàn)該靶點(diǎn)失活與多種腫瘤發(fā)生發(fā)展相關(guān)，對(duì)其機(jī)制的深入探究有助于開(kāi)發(fā)新型抗癌療法。試劑盒檢測(cè)范圍為18.75 pg/mL-1200 pg/mL，適用于基礎(chǔ)科研中探究腫瘤發(fā)生機(jī)制、細(xì)胞周期調(diào)控網(wǎng)絡(luò)、藥物干預(yù)效果評(píng)估等方向，為體外實(shí)驗(yàn)提供可靠的蛋白定量分析工具。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見(jiàn)產(chǎn)品說(shuō)明書。
  • 別名：
    CDKN2A ELISA Kit; CDKN2 ELISA Kit; MTS1 ELISA Kit; Cyclin-dependent kinase inhibitor 2A ELISA Kit; Cyclin-dependent kinase 4 inhibitor A ELISA Kit; CDK4I ELISA Kit; Multiple tumor suppressor 1 ELISA Kit; MTS-1 ELISA Kit; p16-INK4a ELISA Kit; p16-INK4 ELISA Kit; p16INK4A ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates, cell lysates
  • 檢測(cè)范圍：
    18.75 pg/mL-1200 pg/mL
  • 靈敏度：
    4.69 pg/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Cell Biology
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human CDKN2A in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)
    1:1 Average % 106
    Range % 101-112
    1:2 Average % 96
    Range % 92-99
    1:4 Average % 92
    Range % 86-96
    1:8 Average % 94
    Range % 90-99
  • 回收率：
    The recovery of human CDKN2A spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range
    Serum (n=5) 103 99-107
    EDTA plasma (n=4) 93 85-96
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/ml OD1 OD2 Average Corrected
    1200 2.355 2.443 2.399 2.306
    600 1.806 1.784 1.795 1.702
    300 1.333 1.230 1.282 1.189
    150 0.841 0.906 0.874 0.781
    75 0.462 0.460 0.461 0.368
    37.5 0.274 0.290 0.282 0.189
    18.75 0.163 0.160 0.162 0.069
    0 0.095 0.090 0.093 　
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.
  • 基因功能參考文獻(xiàn)：
    1. Increased expression of epithelial and stromal p16(CDKN2A) in all grades of cervical intraepithelial neoplasia and cancer PMID: 30059872
    2. Data indicate a cell regulatory mechanism through which lysine-specific demethylase 2B (KDM2B) promotes triple negative breast cancer (TNBC) cell proliferation by binding to the promoters of cell cycle inhibitors p15INK4B, p16INK4A, and p57KIP2. PMID: 30060056
    3. results suggest that lower P16(INK4A) expression associated with highercancer stem cells (CSCs) markers predicts poor prognostic outcomes and is a promising target in patients with cervical cancer. PMID: 30150594
    4. In this review, we discuss recent findings on the regulation of p16-INK4a by covalent modifications at both transcriptional and post-translational levels. PMID: 30482142
    5. Knockdown of cyclin dependent kinase inhibitor 2A (p16INK4A) in cardiac stem/progenitor cell (hCPC) reverses the senescent phenotype and has an antioxidant effect on aging hCPCs via NF-KAPPA B (NF-kB) signaling. PMID: 29675777
    6. CDKN2A methylation is involved in the carcinogenesis, progression, and metastasis of head and neck squamous cell carcinoma; could be a potential diagnostic and prognostic biomarker (Meta-Analysis) PMID: 30355925
    7. CDKN2A overexpression was cell-type dependent in adenoid cystic carcinoma in the lacrimal gland, while HPV infection was negative. PMID: 29430168
    8. Study reveals the novel function of NOX4 in reprogramming aerobic glycolysis initiated by activated Kras and inactivated p16 in pancreatic ductal adenocarcinoma. PMID: 28232723
    9. we were able to document the loss of p16 protein expression and CDKN2A gene aberrancy in a subset of conventional and fibrosarcomatous dermatofibrosarcoma protuberans cases PMID: 29743142
    10. ARF is a tumor suppressor protein that has a pivotal role in the prevention of cancer development through regulating cell proliferation, senescence, and apoptosis. As a factor that induces senescence, the role of ARF as a tumor suppressor is closely linked to the p53-MDM2 axis, which is a key process that restrains tumor formation. Review. PMID: 29665672
    11. p16/Ki-67 dual immunostaining had comparable sensitivity and improved specificity in screening high-grade cervical intraepithelial neoplasm (HGCIN) or CC when compared with hrHPV detection. Further studies may be beneficial to assess the efficacy of this novel biomarker, which can be potentially used as one of the initial screening assays. PMID: 30249873
    12. Findings outlined in the current study demonstrated that the inhibition of P16 decreased the growth and metastasis potential of BC cells by inhibiting IL-6/JAK2/STAT3 signaling. PMID: 29388151
    13. Loss of P14ARF expression is associated with small intestinal adenocarcinoma. PMID: 30375264
    14. These results...suggest that nucleolar p14ARF can be used as early prognostic marker in chronic liver disease to reliably identify patients with high risk for developing liver cancer PMID: 29228217
    15. a antagonizing mechanism coordinating Arg 138 methylation and Ser 140 phosphorylation to regulates p16 function as well as cellular apoptosis and senescence. PMID: 28120917
    16. The aim of this study was to investigate the expression of p16 and SATB1 proteins in regard to expression of the Ki-67 antigen and available clinicopathological data (i.a. receptor status, staging and grading PMID: 29936452
    17. rognostic impact of p16 can be emphasized in a subgroup of oropharyngeal squamous cell carcinoma (OSCC) patients undergoing surgery. Surgery with sufficient surgical margin may be chosen as the first treatment for HPV-negative OSCC in some cases PMID: 29936482
    18. Low P16INK4A expression is associated with laryngeal squamous cell carcinomas. PMID: 30275203
    19. These results confirm that CDKN2A is a tumor suppressor gene driving human cancer development by inducing cell aneuploidy and cell cycle up-regulation PMID: 30136875
    20. This study demonstrated that p16/Ki-67 dual staining represents an effective method for cervical cancer screening. Application of this method could lead to a reduction of unnecessary colposcopy referrals and misdiagnosis. PMID: 29758205
    21. Non-significant association was seen in the two single nucleotide polymorphisms (SNPs) of CDKAL1 (rs7754840) and CDKN2A/2B (rs10811661) with gestational diabetes mellitus (GDM). PMID: 29544538
    22. In conclusion, this meta-analysis showed that decreased p16(INK4a) expression is associated with lower overall survival rate in patients with STS, and it is an effective biomarker of prognosis. PMID: 29798963
    23. CDKN2A mutation carriers presented more atypical naevi, multiple melanomas, and basal cell carcinoma. PMID: 29405243
    24. hsa_circ_0014717 acts as a potential tumor suppressor that inhibits colorectal cancer growth, partly at least, through upregulating p16 expression. PMID: 29571246
    25. Anti-E2, -L1, and -p16(INK4A) antibodies in sera were determined by western blot. Among 116 samples, 69 (60%) were HPV DNA-positive. Percentages seropositive for anti-E2, -L1, and -p16(INK4A) antibodies were 39.6, 22.4, and 23.3%, respectively. PMID: 29744680
    26. p16 represents a useful supplementary marker for diagnosis of SCLC, even in cases where only cytological material is available PMID: 29566943
    27. this study shows that basaloid squamous cell carcinoma and basal cell carcinoma of the head and neck can be readily distinguished by a limited panel consisting primarily of EMA, and supported by SOX2 and p16 PMID: 27438511
    28. p16 IHC is an independent prognostic biomarker in pleural mesothelioma PMID: 28889523
    29. It plays a role for small intestine-specific gene regulation and alterations of the CDKN2A/CDKN2B locus could affect the pathophysiology of inflammatory bowel disease. PMID: 29063720
    30. p16/Ki-67 dual staining can increase the efficiency of screening methods for cervical cancer. PMID: 29895125
    31. The methylation of the p16 gene promoter could significantly reduce p16 expression, losing its tumor suppressor activity and promoting the development of cervical cancer. PMID: 28617556
    32. Co-administration of VOR did not increase the overall response rate (P = 0.84) or overall survival (OS; P = 0.32). Specifically, no benefit was identified in either de novo or relapsed AML. Mutations in the genes CDKN2A (P = 0.0001), IDH1 (P = 0.004), and TP53 (P = 0.003) were associated with reduced OS PMID: 28765326
    33. The increased expression of p16ink4a may affect the activity of Wnt/betacatenin signaling through modulation of the expression of betacatenin. PMID: 29207089
    34. Alterations in chromatin-remodeling genes and CDKN2A contribute to metastasis of pancreatic neuroendocrine tumors. PMID: 29486199
    35. data suggest that a P16-dependent pathway drives the induction of cellular senescence in dental follicle cells. PMID: 28770470
    36. rs2518719 is a pleiotropic CDKN2A variant associated with the risk of developing pancreatic neuroendocrine tumors PMID: 28008994
    37. Hypermethylation of p14 appears to be an important event in the development of mucoepidermoid carcinoma. High frequency of gene hypermethylation and high incidence of methylation at multiple sites point to the importance of epigenetic phenomena in the pathogenesis of MECs, although with modest impact on clinical parameters. PMID: 29079368
    38. perinatal methylation at CDKN2A is associated with childhood bone development. PMID: 28419547
    39. Final follow-up showed 45 cases of spontaneous lesion regression and 42 cases of persistence with absence of protein p164NK4a in all of them PMID: 29787011
    40. CDKN2A/p16 frequently alters in oral cancer progression with a deletion/loss of function in the recurrent cases displaying its role in aiding several molecular events for the malignant transformations occurring throughout disease progression PMID: 28939073
    41. Data suggest that stromal cyclin-dependent kinase inhibitor p16 (p16) expression is involved in the development and progression of gastric-type mucinous carcinoma (MC-G). PMID: 29848709
    42. Report p16 immunohistochemistry in oropharyngeal squamous cell carcinoma and high-risk human papillomavirus RNA status. PMID: 28621317
    43. CDKN2A/B locus SNPs may impact type 2 diabetes risk by modulating islet gene expression and beta-cell proliferation. PMID: 29432124
    44. miR663 is upregulated in the serum of patients with NPC and NPC cells, and may promote the proliferation and cell cycle progression of NPC cells, at least in part through direct targeting of CDKN2A. PMID: 28765905
    45. Studied CDKN2A/B gene variants and association with increased risk of breast cancer; results show a correlation between the genetic polymorphism, rs10811661, in CDKN2A/B gene and breast cancer. PMID: 28276595
    46. p16 inhibits tenogenic differentiation of tendon stem/progenitor cells via microRNA signaling pathways. PMID: 29036495
    47. Oncogenic signaling induces ARF, and ARF further promotes p53 activation to inhibit proliferation. PMID: 28484034
    48. Data show that p16(INK4a) mRNA expression level was significantly negatively associated with handgrip strength in men but not in women. PMID: 27549351
    49. Significant immunoreactivity for p16(INK4a) was present in about one-fifth of the samples and figured as a surrogate marker of high-risk human papillomavirus infection in squamous cell carcinoma of the nasal vestibule. PMID: 28371015
    50. The p16-/HPV L1- pattern was significantly associated with the regression of CIN1. Moving from cervical intraepithelial neoplasia 1 (CIN1) to CIN2+ over time, p16+/HPV L1+ decreased, and p16+/HPV L1- increased. PMID: 28277314

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Melanoma, cutaneous malignant 2 (CMM2); Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC); Melanoma-astrocytoma syndrome (MASTS)
  • 亞細(xì)胞定位：
    Cytoplasm. Nucleus.
  • 蛋白家族：
    CDKN2 cyclin-dependent kinase inhibitor family
  • 組織特異性：
    Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 1787

    OMIM: 155601

    KEGG: hsa:1029

    STRING: 9606.ENSP00000394932

    UniGene: Hs.512599